All In Biotech

Drug Trial Radar · NCT01996839

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

514

Actual

Start

Dec 2013

Primary completion

May 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Nov 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel

Conditions

  • Inflammation
  • Pain
  • Cataract

Interventions

  • Loteprednol Etabonate Gel (BID)Drug

    One drop of LE gel instilled into the study eye two times per day (BID) for 14 days

  • Loteprednol Etabonate Gel (TID)Drug

    One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.

  • Vehicle (BID)Drug

    One drop of vehicle instilled into the study eye two times per day (BID) for 14 days

  • Vehicle (TID)Drug

    One drop of vehicle instilled into the study eye three times per day (TID) for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsTime frame: 8 days
  2. Percentage of Participants With Grade 0 Pain in the Study Eye.Time frame: 8 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb Incorporated

    Bridgewater, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.